PMID- 1677250
OWN - NLM
STAT- MEDLINE
DCOM- 19910828
LR  - 20131121
IS  - 1100-1801 (Print)
IS  - 1100-1801 (Linking)
VI  - 3
IP  - 1
DP  - 1991
TI  - High performance liquid chromatographic assays of the illicit designer drug 
      "Ecstasy", a modified amphetamine, with applications to stability, partitioning 
      and plasma protein binding.
PG  - 9-14
AB  - Specific, sensitive, reverse-phase high-performance liquid chromatographic (HPLC) 
      assays of 3,4-methylenedioxymethamphetamine (MDMA) and 
      3,4-methylenedioxyamphetamine (MDA) have been devised with analytical 
      sensitivities as low as 2.7 ng/ml of plasma for MDMA and 1.6 ng/ml for MDA, using 
      spectrophotometric detection at 280 nm. The assays were used to determine some 
      properties of MDMA and MDA. Both drugs were stable in aqueous 1 M HCl, and 1 M 
      NaOH solutions at room temperature. The half-life for MDMA was 6.6 h and for MDA 
      was 7.1 h under the extreme conditions of 90 degrees C and 6 M HCl. MDMA and MDA 
      were highly stable for 28 h in plasma at 25 degrees and 39 degrees C. The 
      concentrations of the drugs were unchanged in frozen plasma after 47 days. The 
      apparent red blood cell-plasma partition coefficient determined from assayed 
      concentrations of the drugs in plasma and erythrocytes was 1.45 for both MDMA and 
      MDA. An equation is presented to correct drug concentration in erythrocytes for 
      the trapped equilibrated plasma/buffer in the packed red blood cells. The 
      fraction of MDMA and MDA bound to dog plasma proteins was determined by several 
      methods and it is 0.34-0.40 for both drugs. The extent of protein binding was 
      independent of the drugs' concentration.
FAU - Garrett, E R
AU  - Garrett ER
AD  - College of Pharmacy, J. Hillis Miller Health Center, University of Florida, 
      Gainesville 32610-0494.
FAU - Seyda, K
AU  - Seyda K
FAU - Marroum, P
AU  - Marroum P
LA  - eng
GR  - 6RO1 DA 00743/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Sweden
TA  - Acta Pharm Nord
JT  - Acta pharmaceutica Nordica
JID - 8915967
RN  - 0 (Blood Proteins)
RN  - 0 (Designer Drugs)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/*analogs & derivatives/analysis/blood
MH  - Blood Proteins/*metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Designer Drugs/analysis
MH  - Drug Stability
MH  - Humans
MH  - N-Methyl-3,4-methylenedioxyamphetamine
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
PST - ppublish
SO  - Acta Pharm Nord. 1991;3(1):9-14.